Psychopathology and continuous subcutaneous insulin infusion in type 1 diabetes by Rotella, Francesco et al.
Hindawi Publishing Corporation
The Scientific World Journal
Volume 2013, Article ID 672729, 4 pages
http://dx.doi.org/10.1155/2013/672729
Research Article
Psychopathology and Continuous Subcutaneous
Insulin Infusion in Type 1 Diabetes
Francesco Rotella,1 Caterina Lamanna,1 Ilaria Dicembrini,1
Carlo Faravelli,2 Caterina Calasso,2 and Edoardo Mannucci1
1 Diabetes Agency, Careggi Teaching Hospital, Via delle Oblate 4, 50141 Firenze, Italy
2 Department of Health Sciences, University of Florence, Viale Pieraccini 6, 50139 Firenze, Italy
Correspondence should be addressed to Francesco Rotella; docrot@gmail.com
Received 6 August 2013; Accepted 21 August 2013
Academic Editors: J.-T. Cheng and M. C. Hardoy
Copyright © 2013 Francesco Rotella et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Aim. Continuous subcutaneous insulin infusion (CSII) is used as an option in patients with diabetes failing to multiple daily injec-
tions (MDI). Psychological factors may play a relevant role in the failure to attain therapeutic goals in patients on MDI. This could
lead to an overrepresentation of psychopathology in patients treated with CSII.Methods. A consecutive series of 100 patients with
type 1 diabetes was studied, collectingmain clinical parameters and assessing psychopathology with the self-reported questionnaire
Symptom Checklist 90-revised. Patients on CSII were then compared with those on MDI. Results. Of the 100 enrolled patients, 44
and 56 were on CSII andMDI, respectively. Amongmen, those on CSII were younger than those onMDI; conversely, no difference
in age was observed in women.Women onCSII showed higher scores onmost SymptomChecklist 90 subscales than those onMDI,
whereas no differences were observed in men. Conclusion. Women with type 1 diabetes treated with CSII display higher levels of
psychopathology than those onMDI.This is probably the consequence of the fact that patients selected for CSII are those failing to
MDI. Higher levels of psychopathology could represent a limit for the attainment and maintenance of therapeutic goals with CSII.
1. Introduction
Continuous subcutaneous insulin infusion (CSII) is consid-
ered a therapeutic option for patients with type 1 diabetes
inadequately controlled on multiple daily injections (MDI),
producing beneficial effects on glucose control and quality of
life [1]. However, in systematic reviews and meta-analyses of
randomized trials the improvements associated with CSII are
usually very small [1–3]; in the few available trials in type 2
diabetes, the efficacy ofCSII does not even seem to differ from
that of MDI [4]. On the basis of those results, some authors
are inclined to think that the additional benefits provided
by CSII could be limited [1]. Those opinions can affect the
decisions of authorities, which often limit the reimbursement
of expensive devices unless the clinical benefits are clearly
proven [5].
On the other hand, there are some theoretical reasons
which suggest that randomized clinical trials could under-
estimate the potential benefits of CSII. First of all, patients
enrolled in the clinical trials on CSII are usually already
insulin-treated, thosewere allocated toCSII switch fromMDI
to CSII, and they could need some time to adapt to their new
treatment strategy. Furthermore, available trials on CSII in
type 1 diabetes are performed on patients who do not reach a
satisfactory glycemic control with traditional insulin therapy;
therefore, their characteristics may differ from the average of
individuals with type 1 diabetes. In other terms, it is possible
that those considered for CSII trials are more resistant to any
insulin treatment. In particular, a higher level of psychopa-
thology, leading to unsatisfactory glycemic control withMDI,
could be associated with CSII. In fact, psychological factors
play a relevant role in the attainment and maintenance of
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glycemic targets, and psychopathology is recognized as a
common cause of unsatisfactory blood glucose control [6].
The present survey was designed to verify this hypothesis.
2. Materials and Methods
We studied a consecutive series of 100 outpatients with type 1
diabetes referred to theOutpatient Diabetes Clinic of Careggi
Teaching Hospital in Florence, Italy, between September 3rd
2012 and October 26th 2012. Diagnosis of type 1 diabetes was
based on clinicians’ judgment. Patients with illiteracy and/or
cognitive impairment, to prevent the compilation of the self-
reported questionnaire (see below), were excluded as well as
those who were not familiar with the Italian language. Two
subjects were excluded because of the inadequate knowledge
of the language. The study was approved by the local Ethics
Review Board. All participants provided their informed
consent prior to the enrolment.
Data on diabetes duration, concurrent treatments, and
associated medical conditions were collected from patients’
clinical records, whereas HbA1c wasmeasured with anHPLC
method (IFCC standard, Biorad, Hercules, CA, USA) within
7 days from the visit. Furthermore, psychopathology was
assessed during a routine clinic visit by means of the self-
reported questionnaire Symptom Checklist 90-revised (SCL-
90-R) [7], a psychometric instrument devoted to the identifi-
cation of the psychopathological distress. This psychometric
test provides scores for different psychopathological areas
(e.g., anxiety, depression, obsessive-compulsive symptoms,
etc.), without predefined pathological thresholds for each
scale. As a consequence, SCL-90 measures psychopathology
as a dimension, but it does not allow formal categorical diag-
noses. Only questionnaires with over 90% of completed items
were considered valid for analysis.
Data were summarized as mean ± SD if normally dis-
tributed, otherwise they were summarized as median (quar-
tiles). Scores of SCL-90 were assumed to be not normally dis-
tributed. Comparisons across groups were performed using
Student’s 𝑡-test or Mann-Whitney 𝑈 test whenever appropri-
ate. Those comparisons were performed separately for gen-
der, considering the differences in psychopathology between
men and women in the general population [8].The Statistical
Package for the Social Sciences forWindows SPSS (IBM, 2011)
version 20.0 was used for data analysis.
3. Results and Discussion
3.1. Results. Of the 100 enrolled patients (61 and 39 women
and men, resp.), 27 were affected by diabetic retinopathy and
14 by microalbuminuria. In addition, 4 patients complained
of symptomatic peripheral diabetic neuropathy, whereas no
patient reported diabetes-related visual impairment, symp-
tomatic arteriopathy of lower limbs, or previous major car-
diovascular or cerebrovascular events.Thirteen patients were
also receiving treatment withmetformin: 12 were treatedwith
ACE inhibitors or angiotensin receptor blockers and onewith
acetylsalicylic acid. None of the patients reported a history of
psychiatric disorders, andnonewas treatedwith psychotropic
medication, except two women that reported the use of low-
dose benzodiazepines.
Among those 100 patients, 44 and 56 were on CSII and
MDI, respectively. All patients on CSII had been previously
treated with MDI. All patients on CSII except 3 had switched
fromMDI to CSII more than 3 months before enrolment.
The characteristics of patients within each treatment
group are reported in Table 1. Among men, those on CSII
were significantly younger than those onMDI, whereas dura-
tion of diabetes and HbA1c did not differ across groups.
All enrolled patients completed over 90% of items of
SCL-90. Overall, SCL-90 total and subscale scores were not
significantly different between women and men (data not
shown); conversely, women on CSII showed higher scores on
most SCL-90 subscales, whereas no differences between CSII
and MDI were observed in men.
3.2. Discussion. The present survey suggests that, at least
among women, patients who are treated with CSII dis-
play higher levels of psychopathology than those on MDI.
Although a cross-sectional study does not allow any causal
inference, it seems very unlikely that CSII, which has been
associated with higher treatment satisfaction and improved
quality of life [1, 9], produces psychopathology. On the other
hand, patients with psychological disturbances, who may
experience greater difficulties in reaching andmaintaining an
adequate glucose control, could have a greater chance of being
treated with CSII. In fact, a previous study had reported a
higher prevalence of depressive symptoms in patients onCSII
[10] without exploring other psychopathological areas. In the
present survey, patients treated with CSII had higher scores
on multiple areas (e.g., anxiety, depression, and obsessive-
compulsive symptoms), suggesting a difference in overall psy-
chopathology, rather than a specific drive related to depres-
sion. The lack of significant differences in men could be due
either to a lower prevalence of psychopathology in the male
gender (which was not observed in the present sample) or to
a greater impact of psychological disturbances on diabetes
management and control in females.
The differences in psychopathology can have a relevant
prognostic impact. There is wide evidence that mental disor-
ders (e.g., depressive disorders and eating disorders) are asso-
ciated with impaired glycemic control in patients with type 1
diabetes [11]; furthermore, the presence of psychopathologi-
cal symptoms, even without a full-blown psychiatric disorder
diagnosis, can be sufficient to affect glucose control [11]. If
patients on CSII have a higher psychopathology, they should
also be expected to encounter greater difficulties in attaining
(and maintaining) therapeutic targets. Psychological prob-
lems and mental disorders are often cited as barriers to treat-
ment adherence [6]. However, it is also possible that some
psychological disturbances affect glucose control through
different mechanisms, such as the activation of hormonal or
inflammatory pathways [12].
Another interesting finding is that men on CSII are
younger than those on MDI, whereas this difference is not
evident among women. It can be speculated that the use
of newer technologies is easier for younger individuals, as
observed for smartphones or other digital devices [13]. In this
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Table 1: Characteristics of patients on CSII and MDI.
Characteristics Women Men
CSII MDI CSII MDI
Number 27 34 17 22
Age (years) 39.8 ± 14.5 39.4 ± 10.7 37.0 ± 9.5∗ 43.3 ± 8.9
Duration of diabetes (years) 16 [11; 25] 18 [11; 25] 12 [7; 16] 10 [7; 14]
HbA1c (%) 7.4 [7.2; 7.7] 7.5 [6.8; 8.1] 7.6 [7.3; 7.7] 7.4 [7.1; 7.8]
(mmol/mol) 57 [55; 61] 58 [51; 65] 60 [57; 61] 58 [54; 62]
SCL-90 GSI 2.2 [1.3; 2.3]∗∗ 1.6 [0.9; 2.1] 2.0 [1.5; 2.2] 1.5 [1.2; 2.1]
SCL-90 PST 86 [72; 89]∗ 75 [54; 85] 81 [70; 88] 77 [60; 87]
SCL-90 PSDI 2.3 [2.0; 2.4]∗∗ 2.0 [1.6; 2.3] 2.2 [1.9; 2.3] 2.0 [1.7; 2.2]
SCL-90 Somatization 1.8 [1.2; 2.0] 1.6 [1.2; 1.7] 1.5 [1.2; 1.7] 1.5 [1.2; 1.8]
SCL-90 Obsessive-Compulsive 2.1 [1.4; 2.5]∗∗ 1.4 [0.8; 2.0] 1.8 [1.2; 2.2] 1.4 [0.9; 2.1]
SCL Interpersonal Sensitivity 2.4 [1.6; 2.7]∗ 1.9 [1.1; 2.4] 2.1 [1.6; 2.6] 1.8 [1.4; 2.4]
SCL-90 Depression 2.5 [1.7; 2.8]∗∗ 2.1 [1.4; 2.5] 2.4 [2.0; 2.5] 2.0 [1.6; 2.5]
SCL-90 Anxiety 2.2 [1.1; 2.3]∗∗ 1.3 [0.9; 1.9] 1.9 [1.4; 2.1] 1.5 [1.1; 1.9]
SCL-90 Anger/Hostility 2.3 [1.5; 2.7]∗ 1.8 [1.0; 2.3] 2.5 [1.8; 2.7]∗ 2.1 [1.4; 2.2]
SCL-90 Phobic Anxiety 1.6 [1.0; 1.7]∗ 1.0 [0.6; 1.4] 1.3 [0.7; 1.6] 0.9 [0.6; 1.6]
SCL-90 Paranoid Ideation 2.3 [1.5; 2.5] 2.0 [1.3; 2.5] 2.5 [1.7; 2.7] 2.1 [1.5; 2.7]
SCL-90 Psychoticism 1.8 [1.1; 2.2]∗ 1.2 [0.5; 1.9] 1.7 [1.3; 2.1] 1.2 [1.0; 1.9]
CSII: Continuous subcutaneous insulin infusion; MDI: Multiple daily injections; HbA1c: Hemoglobin A1c; SCL-90: Symptom Checklist 90; GSI: General
Symptomatic Index; PST: Positive Symptom Total; PSDI: Positive Symptom Distress Index. Data are expressed as mean ± SD or median [quartiles]. ∗𝑃 < 0.05
and ∗∗𝑃 < 0.01 versus CSII.
perspective, the younger age ofmen onCSII is not surprising.
On the other hand, the fact that such difference is not
observed in women may depend on other factors. In par-
ticular, it is possible that younger women experience grater
discomfort in using a device which may be perceived as a
limitation in exposing one’s body.
Some limitations of the present study should be recog-
nized. First of all, as already stated above, the cross-sectional
design does not allow any causal inference. Furthermore,
the size of the sample is limited, preventing the detection of
smaller differences across groups. The sample was composed
of patients referred to a main academic facility for the treat-
ment of diabetes, who cannot be considered representative
of individuals with type 1 diabetes in the general population;
in fact, the proportion of those on CSII was markedly higher
than that (about 4%) reported for the whole country [14]. In
addition, the study wasmonocentric; for this reason, the allo-
cation of patients to CSII could reflect local, rather than gen-
eral, attitudes. A further limitation is represented by the fact
that psychopathology was assessed only by the means of
a self-reported questionnaire; although this instrument has
been widely validated, its reliability cannot be compared to
that of interviews. For this same reason, it was not possible
to formulate psychiatric diagnoses using DSM-IV-R criteria
[15]. Despite these limitations, the observation that psychopa-
thology differs in those using CSII is potentially interesting,
and it deserves to be further investigated in larger samples.
4. Conclusion
Thefact that patients addressed toCSII, being failures toMDI,
have a higher psychopathology than average individuals with
type 1 diabetes should be taken into account when assessing
the effects of treatment with CSII. In fact, psychological dis-
turbances could be amajor factor leading to inadequate treat-
ment response, preventing the attainment of therapeutic tar-
gets.
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